Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Therapeutics

Background:

• Nanoparticle formulations offer novel strategies for targeted delivery of therapeutic agents to tumors.
• Receptor-Targeted Nanocomplexes (RTNs) utilize PEGylated lipids and RGD peptides for enhanced cellular uptake and endosomal escape.

Purpose of the Study:

• To evaluate the efficacy of RTNs for gene delivery and cancer therapy in a neuroblastoma mouse model.
• To assess the impact of integrin-targeting peptides on transfection efficiency and therapeutic outcomes.

Main Methods:

• RTNs were formulated with plasmid DNA encoding luciferase, IL-2, or IL-12 genes.
• Nanoparticles self-assembled to approximately 100 nm and were administered intravenously to mice with subcutaneous neuroblastoma.
• Tumor growth, gene expression, plasmid biodistribution, and immune responses were monitored.

Main Results:

• RTNs demonstrated significantly higher luciferase expression in tumors compared to other organs.
• Integrin-targeting RTNs enhanced tumor transfection by two-fold over non-targeted complexes.
• RTNs carrying IL-2 and IL-12 genes resulted in a 75% reduction in tumor size and improved long-term survival, with evidence of T-cell mediated tumor rejection.

Conclusions:

• Integrin-targeted RTNs are an effective platform for targeted gene delivery and cancer therapy.
• The RTN formulation promotes gene expression in tumors and mediates significant anti-tumor immune responses.
• This nanotechnology holds potential for broader applications in developing advanced cancer therapeutics.